Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

PURPOSE: To compare the receipt of clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) in patients ≥ 55 years old with refractory or relapsed acute myelogenous leukemia (AML). PATIENTS AND METHODS: Patients were randomly assigned to receive either clofarabine (Clo) 40 mg/m(2) or...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Faderl, Stefan, Wetzler, Meir, Rizzieri, David, Schiller, Gary, Jagasia, Madan, Stuart, Robert, Ganguly, Siddhartha, Avigan, David, Craig, Michael, Collins, Robert, Maris, Michael, Kovacsovics, Tibor, Goldberg, Stuart, Seiter, Karen, Hari, Parameswaran, Greiner, Jochen, Vey, Norbert, Recher, Christian, Ravandi, Farhad, Wang, Eunice S., Vasconcelles, Michael, Huebner, Dirk, Kantarjian, Hagop M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2012
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874149/
https://ncbi.nlm.nih.gov/pubmed/22585697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.9743
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller